The market expects Gilead Sciences (GILD) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended March 2025. This widely-known consensus ...

Gilead Sciences (GILD) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to ...

At current levels, we believe GILD scores above BMY, buoyed by solid fundamentals, potential approval of lenacapavir for HIV ...

Delve into the landscape of biotech companies developing treatments for HIV and find out if we are getting closer to a cure.

Research in the Sundquist lab laid the foundations for the development of lenacapavir, a drug that prevents HIV infection ...

A group of academics is arguing that countries seeking access to a groundbreaking HIV prevention drug from Gilead Sciences ...

Focused on elevating Abu Dhabi as a hub for groundbreaking medical research, the partnership aims to enhance treatment ...

Wesley Sundquist, a biochemist at University of Utah, and Tomas Cihlar, a virologist at Gilead, a biopharmaceutical company, ...

With that said, let's consider two top dividend stocks that should navigate the current storm relatively well and continue ...

Gilead Sciences’ sponsorship of a conference Wi-Fi network has landed it in hot water. | Gilead Sciences’ sponsorship of a conference Wi-Fi network has landed it in hot water. The PMCPA ruled the ...

Human immunodeficiency virus, if untreated, causes acquired immunodeficiency syndrome (AIDS), and death. HIV is almost entirely preventable by using condoms, or by taking PrEP drugs. PrEP drugs do not ...